apraclonidine has been researched along with Ptosis, Eyelid in 15 studies
apraclonidine: relieves postoperative intraocular pressure following trabeculoplasty; RN given refers to parent cpd
apraclonidine : An imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Apraclonidine (0." | 5.33 | The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis. ( Acaroglu, G; Firat, E; Kansu, T; Kavuncu, S; Koc, F, 2005) |
| " Topical instillation of apraclonidine may represent a nonsurgical option for treatment of mild blepharoptosis in patients with light irides as it both elevates the upper eyelid margin and induces miosis, resulting in an increase in iris show and corresponding enhanced perception of upper eyelid elevation." | 3.88 | Effect of iris show on perceived upper eyelid height. ( Clark, TJE; Evans, JA; Shriver, EM; Wang, K, 2018) |
| "Apraclonidine is an alpha2-adrenergic agonist, which causes Muller muscles to contract quickly elevating the upper eyelid 1-3 mm." | 2.43 | The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. ( Scheinfeld, N, 2005) |
| "Apraclonidine hydrochloride is a topical ophthalmic solution with selective alpha-2 and weak alpha-1 receptor agonist activity that has the ability to elevate the eye lid." | 1.46 | Apraclonidine in the treatment of ptosis. ( Jankovic, J; Vijayakumar, D; Wijemanne, S, 2017) |
| "Apraclonidine (0." | 1.33 | The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis. ( Acaroglu, G; Firat, E; Kansu, T; Kavuncu, S; Koc, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kraker, JA | 1 |
| Tajfirouz, DA | 1 |
| Bhatti, MT | 1 |
| Chen, JJ | 1 |
| Agha, M | 1 |
| Ismail, H | 1 |
| Sawaya, R | 1 |
| Salameh, J | 1 |
| Wijemanne, S | 1 |
| Vijayakumar, D | 1 |
| Jankovic, J | 1 |
| Osaki, TH | 1 |
| Osaki, MH | 1 |
| Evans, JA | 1 |
| Clark, TJE | 1 |
| Wang, K | 1 |
| Shriver, EM | 1 |
| Escrivá, E | 1 |
| Martínez-Costa, L | 1 |
| Steinsapir, KD | 1 |
| Groth, MJ | 1 |
| Boxrud, CA | 1 |
| McInnis, CP | 1 |
| Haynor, DR | 1 |
| Francis, CE | 1 |
| Brown, M | 1 |
| Malem, A | 1 |
| Shin, RK | 1 |
| Cheek, AG | 1 |
| Scheinfeld, N | 1 |
| Koc, F | 1 |
| Kavuncu, S | 1 |
| Kansu, T | 1 |
| Acaroglu, G | 1 |
| Firat, E | 1 |
| Chu, EA | 1 |
| Byrne, PJ | 1 |
| Singer, M | 1 |
1 review available for apraclonidine and Ptosis, Eyelid
| Article | Year |
|---|---|
The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face.
Topics: Adrenergic alpha-Agonists; Blepharoptosis; Botulinum Toxins; Clonidine; Humans; Neuromuscular Agents | 2005 |
1 trial available for apraclonidine and Ptosis, Eyelid
| Article | Year |
|---|---|
Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial.
Topics: Blepharoptosis; Clonidine; Humans; Myasthenia Gravis; Ophthalmic Solutions; Retrospective Studies | 2023 |
13 other studies available for apraclonidine and Ptosis, Eyelid
| Article | Year |
|---|---|
Tachyphylaxis With Sustained Apraclonidine Use in the Treatment of Ptosis Associated With Horner Syndrome.
Topics: Blepharoptosis; Clonidine; Horner Syndrome; Humans; Tachyphylaxis | 2023 |
Apraclonidine in the treatment of ptosis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Blepharoptosis; Botulinum Toxins; Clo | 2017 |
Re: Apraclonidine in the treatment of ptosis.
Topics: Blepharoptosis; Clonidine; Humans | 2017 |
Effect of iris show on perceived upper eyelid height.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Blepharoptosis; Cl | 2018 |
[Incomplete Horner's syndrome as a presenting sign of fourth ventricle ependymoma].
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Blepharoptosis; Cerebral Ventricle Neoplasms; Clonidine | 2013 |
Persistence of Upper Blepharoptosis After Cosmetic Botulinum Toxin Type A.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Blepharoptosis; Botulinum Toxins, Type A; Clonidine; Ey | 2015 |
Horner syndrome in fibromuscular dysplasia without carotid dissection.
Topics: Adrenergic alpha-2 Receptor Agonists; Blepharoptosis; Carotid Artery, Internal, Dissection; Clonidin | 2016 |
Preventing, identifying, and managing cosmetic procedure complications, part 1: soft-tissue augmentation and botulinum toxin injections.
Topics: Adrenergic alpha-2 Receptor Agonists; Blepharoptosis; Botulinum Toxins; Clonidine; Cosmetic Techniqu | 2016 |
Unequal pupils and ptosis.
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Anisocoria; Blepharoptosis; Carotid Arteries; Clonidine; | 2017 |
Teaching NeuroImages: Positive apraclonidine test in Horner syndrome.
Topics: Adrenergic alpha-Agonists; Adult; Blepharoptosis; Clonidine; Diskectomy; Female; Horner Syndrome; Hu | 2011 |
The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis.
Topics: Adrenergic alpha-Agonists; Adult; Anisocoria; Blepharoptosis; Clonidine; Diabetic Neuropathies; Fema | 2005 |
Pharmacologic reversal of Horner's syndrome-related ptosis with apraclonidine.
Topics: Adrenergic alpha-Agonists; Adult; Blepharoptosis; Clonidine; Female; Horner Syndrome; Humans; Treatm | 2007 |
Botulinum toxin treatment of essential blepharospasm and hemifacial spasm.
Topics: Adrenergic alpha-Agonists; Blepharoptosis; Blepharospasm; Botulinum Toxins; Clonidine; Facial Muscle | 1996 |